Ovid Therapeutics (OVID) Return on Capital Employed (2017 - 2026)
Ovid Therapeutics' (OVID) quarterly Return on Capital Employed came in at 27.67% in Q1 2026, up 4580.0% YoY from 0.59% in Q1 2025, and up 35.39% on a QoQ basis from 42.82% in Q4 2025.
Ovid Therapeutics (OVID) Return on Capital Employed (2017 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 10 years of Return on Capital Employed data on file, last reported at 27.67% in Q1 2026.
- Quarterly Return on Capital Employed rose 4580.0% year-over-year to 27.67% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.67% (up 4580.0% YoY) and the FY2025 annual result came in at 37.47%, up 2006.0% from the prior year.
- Return on Capital Employed climbed to 27.67% in Q1 2026, from 42.82% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 27.67% in Q1 2026 to a low of 73.47% in Q1 2025.
- A 5-year average of 51.83% and a median of 48.06% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 10304 bps — and 2026, when it jumped 4580 bps.
- Tracing OVID's Return on Capital Employed over 5 years: stood at 36.27% in 2022, then slumped by 33 bps to 48.17% in 2023, then sank by 48 bps to 71.22% in 2024, then surged by 40 bps to 42.82% in 2025, then surged by 35 bps to 27.67% in 2026.
- The last three Return on Capital Employed figures came in at 27.67% (Q1 2026), 42.82% (Q4 2025), and 64.01% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -27.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.67% |
| Dec 31, 2025 | -42.82% |
| Sep 30, 2025 | -64.01% |
| Jun 30, 2025 | -58.87% |
| Mar 31, 2025 | -73.47% |
| Dec 31, 2024 | -71.22% |
| Sep 30, 2024 | -70.23% |
| Jun 30, 2024 | -61.54% |
| Mar 31, 2024 | -47.94% |
| Dec 31, 2023 | -48.17% |
| Sep 30, 2023 | -43.67% |
| Jun 30, 2023 | -41.68% |
| Mar 31, 2023 | -37.99% |
| Dec 31, 2022 | -36.27% |
| Dec 31, 2021 | 66.77% |
| Sep 30, 2021 | 63.70% |
| Jun 30, 2021 | 57.41% |
| Mar 31, 2021 | 82.24% |
| Dec 31, 2020 | -131.98% |
| Sep 30, 2020 | -152.63% |